CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS

NCT07347418 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Refractory Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)
Relapsed Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)/AML
Myelodysplastic Syndrome
AML (Acute Myeloid Leukemia)

Interventions

DRUG: CD64 CAR T Cells

Sponsor

University of Colorado, Denver